Back to Journals » Journal of Healthcare Leadership » Volume 2

Identification and reduction of adverse drug reactions

Authors Thompson D, Sharp RP

Published 7 July 2010 Volume 2010:2 Pages 43—48

DOI https://doi.org/10.2147/JHL.S8022

Review by Single-blind

Peer reviewer comments 2


Southwestern Oklahoma

State University, Weatherford, Oklahoma, USA

Abstract: Adverse drug reactions (ADRs) are a significant challenge to health care leaders. Serious ADRs increase the morbidity and mortality of patients and create a significant financial impact on health care costs. There are a number of challenges in identifying and reducing the incidence of ADRs. Worldwide, developed countries primarily utilize voluntary systems to identify ADRs and assess their risk to specific populations of patients. All of these systems have significant limitations. The explosion of biomedical research also challenges the clinician to uncover all the literature available concerning particular ADRs. Once identified, assessing causality in a specific patient-drug scenario can be problematic despite the number of scales, algorithms, and nomograms available. Finally, pharmacogenomics is discussed and the implications of personalized genomic medicine on ADRs are described. Pharmacogenomics promises the best possible hope for a significant reduction of clinically important ADRs in the future, although hurdles remain for its’ widespread clinical application.

Keywords: adverse drug reactions, surveillance, pharmacogenomics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]